ReviewCancer biology & medicine2014
Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma.
Review in Cancer biology & medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 76 citations in OpenAlex.
- Three antigen-loading methods in dendritic cell vaccines for metastatic melanoma.Melanoma research · 2018Trial
- Article
- Therapeutic melanoma vaccines: Platforms, neoantigen strategies, and emerging combination immunotherapies.Therapeutic advances in vaccines and immunotherapy · 2026Review
- Article
- Melatonin as a Repurposed Drug for Melanoma Treatment.Medical sciences (Basel, Switzerland) · 2023Review
- Skin cancer, including related pathways and therapy and the role of luteolin derivatives as potential therapeutics.Medicinal research reviews · 2022Review
- Perspectives for Combining Viral Oncolysis With Additional Immunotherapies for the Treatment of Melanoma.Frontiers in molecular biosciences · 2022Review
- Investigation of Lupeol as Anti-Melanoma Agent: An In Vitro-In Ovo Perspective.Current oncology (Toronto, Ont.) · 2021Article
- Article
- Advances in Targeting Cutaneous Melanoma.Cancers · 2021Review
- Review
- Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges.Frontiers in oncology · 2021Review
- Factors Determining Long-Term Antitumor Responses to Immune Checkpoint Blockade Therapy in Melanoma.Frontiers in immunology · 2021Review
- Targeting ERK beyond the boundaries of the kinase active site in melanoma.Molecular carcinogenesis · 2019Review
- A Potential Therapy Using Engineered Stem Cells Prevented Malignant Melanoma in Cellular and Xenograft Mouse Models.Cancer research and treatment · 2019Article
- Ethanolic Extract ofOxidative medicine and cellular longevity · 2019Article
- The Novel Combination of Nitroxoline and PD-1 Blockade, Exerts a Potent Antitumor Effect in a Mouse Model of Prostate Cancer.International journal of biological sciences · 2019Article
- Holistic view of patients with melanoma of the skin: how can health systems create value and achieve better clinical outcomes?Ecancermedicalscience · 2019Review
- A 3D Organotypic Melanoma Spheroid Skin Model.Journal of visualized experiments : JoVE · 2018Article
- From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?Current oncology reports · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Melanoma is the deadliest form of skin cancer and has an incidence that is rising faster than any other solid tumor. Metastatic melanoma treatment has considerably progressed in the past five years with the introduction of targeted therapy (BRAF and MEK inhibitors) and immune checkpoint blockade (anti-CTLA4, anti-PD-1, and anti-PD-L1). However, each treatment modality has limitations. Treatment with targeted therapy has been associated with a high response rate, but with short-term responses. Conversely, treatment with immune checkpoint blockade has a lower response rate, but with long-term responses. Targeted therapy affects antitumor immunity, and synergy may exist when targeted therapy is combined with immunotherapy. This article presents a brief review of the rationale and evidence for the potential synergy between targeted therapy and immune checkpoint blockade. Challenges and directions for future studies are also proposed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.